NCT02716935

Brief Summary

The purpose of this study is to assess the effect of a mixture of prebiotics included in a food supplement on microbiota diversity and functionality, and to explore its subsequent effects on linear growth velocity and morbidity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
153

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2016

Completed
29 days until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
22 days until next milestone

First Posted

Study publicly available on registry

March 23, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2018

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
Last Updated

June 11, 2020

Status Verified

June 1, 2020

Enrollment Period

2.1 years

First QC Date

February 1, 2016

Last Update Submit

June 8, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Fecal microbiota range-weighted richness

    Composition of fecal microbiota will be determined by Illumina sequencing from which range-weighted richness will be calculated

    6 months

  • Mean concentration of short-chain fatty acids in stool

    Concentration of short-chain fatty acids (acetate, butyrate and propionate) will be measured by Gas Chromatography

    6 months

Secondary Outcomes (11)

  • Frequency of digestive intolerance symptoms (flatulence, abdominal pain, regurgitation, vomiting, or diarrhea)

    once every week during the first month of supplementation

  • Stool consistency

    Once every week during the first month of supplementation

  • Stool frequency per day

    6 months

  • Mean stool pH

    once every week during the first month of supplementation

  • Calprotectin concentration in stool

    at inclusion, 3 months and 6months after inclusion

  • +6 more secondary outcomes

Study Arms (3)

Fortified lipid based nutrient supplement

EXPERIMENTAL

lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin

Dietary Supplement: Fortified lipid based nutrient supplement

lipid based nutrient supplement

ACTIVE COMPARATOR

lipid based nutrient supplement (Nutributter)

Dietary Supplement: lipid based nutrient supplement

non intervention group

NO INTERVENTION

This group will not be supplemented

Interventions

6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide

Fortified lipid based nutrient supplement

Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.

lipid based nutrient supplement

Eligibility Criteria

Age24 Weeks - 26 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • month old infants
  • Weight for height and height for age z-score above -2
  • Permanent resident of the area and not intending to move for the next 6 months for more than a week
  • No chronic antibiotic treatment
  • Exempt of any current serious illness
  • Still breastfed.

You may not qualify if:

  • Moderate or severe malnutrition (weight for height or height for age z-score below -2)
  • non-permanent residence in the study area,
  • the presence of any congenital anomalies in the child or mental/physical disease of the mother that can interfere with child feeding
  • a chronic antibiotic treatment i.e. more than 6 weeks treatment at the time of enrolment
  • a history of allergy to a constituent of the supplement
  • a serious current illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRSS/DRO

Bobo-Dioulasso, Houet, 01 BP 545, Burkina Faso

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 1, 2016

First Posted

March 23, 2016

Study Start

March 1, 2016

Primary Completion

April 24, 2018

Study Completion

November 1, 2019

Last Updated

June 11, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will share

Upon publication of the main findings, data will be shared on a public repository and made publicly available on request as per recently published guidance and regulations (BMJ 2016;352:i255)

Locations